NasdaqCM - Delayed Quote USD

BioLineRx Ltd. (BLRX)

0.6116 +0.0363 (+6.31%)
At close: April 26 at 4:00 PM EDT
0.6200 +0.01 (+1.37%)
After hours: April 26 at 5:51 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BLRX

Recent News: BLRX

View More
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
PR Newswire 11 days ago
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
PR Newswire 18 days ago
BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx Announces $6 Million Registered Direct Offering
PR Newswire 27 days ago
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
Insider Monkey last month

BLRX: First Aphexda Sales Recognized
Zacks Small Cap Research last month
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
PR Newswire last month
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024

BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
PR Newswire last month
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
PR Newswire last month
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
PR Newswire last month
BLRX: Poster Presentations

BLRX: Poster Presentations
Zacks Small Cap Research 2 months ago
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
InvestorPlace 2 months ago
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
PR Newswire 2 months ago
View More

Related Tickers

PLX Protalix BioTherapeutics, Inc.
1.1500
-2.54%
 
ENLV Enlivex Therapeutics Ltd.
1.4400
-0.69%
 
CANF Can-Fite BioPharma Ltd.
1.9800
+3.12%
 
EVGN Evogene Ltd.
0.6251
-4.91%
 
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%
 
CGEN Compugen Ltd.
1.9200
+1.05%
 
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%
 
OCUP Ocuphire Pharma, Inc.
1.6100
+4.89%
 
PLUR Pluri Inc.
5.36
+2.23%
 
CKPT Checkpoint Therapeutics, Inc.
1.4300
+0.70%